198 related articles for article (PubMed ID: 36671672)
1. In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations.
Ghufran M; Ullah M; Khan HA; Ghufran S; Ayaz M; Siddiq M; Abbas SQ; Hassan SSU; Bungau S
Bioengineering (Basel); 2023 Jan; 10(1):. PubMed ID: 36671672
[TBL] [Abstract][Full Text] [Related]
2. Virtual screening and structure-based 3D pharmacophore approach to identify small-molecule inhibitors of SARS-CoV-2 M
Elseginy SA
J Biomol Struct Dyn; 2022; 40(24):13658-13674. PubMed ID: 34676801
[TBL] [Abstract][Full Text] [Related]
3. In Silico Identification of Lead Compounds for Pseudomonas Aeruginosa PqsA Enzyme: Computational Study to Block Biofilm Formation.
Shahab M; Danial M; Khan T; Liang C; Duan X; Wang D; Gao H; Zheng G
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979940
[No Abstract] [Full Text] [Related]
4. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
[TBL] [Abstract][Full Text] [Related]
5. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
[TBL] [Abstract][Full Text] [Related]
6. Finding potent inhibitors for COVID-19 main protease (M
Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
[TBL] [Abstract][Full Text] [Related]
7. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
8. A Computer-Aided Drug Design Approach to Predict Marine Drug-Like Leads for SARS-CoV-2 Main Protease Inhibition.
Gaudêncio SP; Pereira F
Mar Drugs; 2020 Dec; 18(12):. PubMed ID: 33322052
[TBL] [Abstract][Full Text] [Related]
9. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics.
Hassan A; Arafa RK
J Biomol Struct Dyn; 2022 Oct; 40(17):7815-7828. PubMed ID: 33749545
[TBL] [Abstract][Full Text] [Related]
10. Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study.
Sen D; Debnath P; Debnath B; Bhaumik S; Debnath S
J Biomol Struct Dyn; 2022 Feb; 40(2):941-962. PubMed ID: 32948116
[TBL] [Abstract][Full Text] [Related]
11. Identification of natural compounds as potent inhibitors of SARS-CoV-2 main protease using combined docking and molecular dynamics simulations.
Jairajpuri DS; Hussain A; Nasreen K; Mohammad T; Anjum F; Tabish Rehman M; Mustafa Hasan G; Alajmi MF; Imtaiyaz Hassan M
Saudi J Biol Sci; 2021 Apr; 28(4):2423-2431. PubMed ID: 33526965
[TBL] [Abstract][Full Text] [Related]
12. In Silico Identification of New Anti-SARS-CoV-2 Main Protease (M
Onyango H; Odhiambo P; Angwenyi D; Okoth P
J Trop Med; 2022; 2022():3697498. PubMed ID: 36263438
[TBL] [Abstract][Full Text] [Related]
13. In Silico Prediction of Novel Inhibitors of SARS-CoV-2 Main Protease through Structure-Based Virtual Screening and Molecular Dynamic Simulation.
Halim SA; Waqas M; Khan A; Al-Harrasi A
Pharmaceuticals (Basel); 2021 Sep; 14(9):. PubMed ID: 34577596
[TBL] [Abstract][Full Text] [Related]
14. Exploration of Novel Lichen Compounds as Inhibitors of SARS-CoV-2 Mpro: Ligand-Based Design, Molecular Dynamics, and ADMET Analyses.
Gupta A; Sahu N; Singh AP; Singh VK; Singh SC; Upadhye VJ; Mathew AT; Kumar R; Sinha RP
Appl Biochem Biotechnol; 2022 Dec; 194(12):6386-6406. PubMed ID: 35921031
[TBL] [Abstract][Full Text] [Related]
15. Phenylbenzopyrone of Flavonoids as a Potential Scaffold to Prevent SARSCoV-2 Replication by Inhibiting its M
Potshangbam AM; Nongdam P; Kumar AK; Rathore RS
Curr Pharm Biotechnol; 2021; 22(15):2054-2070. PubMed ID: 33504301
[TBL] [Abstract][Full Text] [Related]
16. Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach.
Ahmad S; Waheed Y; Ismail S; Najmi MH; Ansari JK
J Mol Liq; 2021 May; 330():115636. PubMed ID: 33612899
[TBL] [Abstract][Full Text] [Related]
17. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
Mandour YM; Zlotos DP; Alaraby Salem M
J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
[TBL] [Abstract][Full Text] [Related]
18. Discovery of New Hydroxyethylamine Analogs against 3CL
Kumar S; Sharma PP; Shankar U; Kumar D; Joshi SK; Pena L; Durvasula R; Kumar A; Kempaiah P; Poonam ; Rathi B
J Chem Inf Model; 2020 Dec; 60(12):5754-5770. PubMed ID: 32551639
[TBL] [Abstract][Full Text] [Related]
19. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
[TBL] [Abstract][Full Text] [Related]
20. Identification of 1H-purine-2,6-dione derivative as a potential SARS-CoV-2 main protease inhibitor: molecular docking, dynamic simulations, and energy calculations.
Nada H; Elkamhawy A; Lee K
PeerJ; 2022; 10():e14120. PubMed ID: 36225900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
